Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast Cancer
JAMA Network Open · 2026
DOI: 10.1001/jamanetworkopen.2026.5014 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2026. Verfasst von José P Leone und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Hauptthemen laut MEDLINE: Inflammatory Breast Neoplasms, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Inflammatory breast cancer (IBC) is an aggressive form of cancer for which trimodality therapy (TMT) is standard, but TMT use may be decreasing. Survival outcomes between patients with IBC and non-IBC by tumor subtype are unclear, and survival trends over time have not been reported.
Objective
To compare breast cancer (BC)–specific survival (BCSS) and overall survival (OS) between IBC and non-IBC by tumor subtype, and to examine trends in TMT use and survival over time. Design, Setting, and Participants This cohort study used population-based data from the Surveillance, Epidemiology, and End Results program. Patients with stage III BC diagnosed between 2010 and 2020 were categorized as having IBC (T4d) and non-IBC. TMT included neoadjuvant systemic therapy, mastectomy, dissection of more than 5 axillary nodes, and adjuvant radiation. Data analysis was conducted from January to October 2024. Exposure Diagnosis of IBC and receipt of TMT. Main Outcomes and Measures BCSS and OS between IBC and non-IBC were evaluated stratified by tumor subtype. Multivariable Cox models were used to estimate adjusted hazard ratios (aHRs) across subtypes and to assess trends in BCSS and OS over time.
Results
Among 47 702 patients with stage III BC (3227 with IBC [6.8%] and 44 475 with non-IBC [93.2%]), the median (IQR) age at diagnosis was 57 (47-68) years, and 47 215 (99.0%) were women. Across all tumor subtypes, IBC was associated with worse BCSS compared with non-IBC, including hormone receptor–positive, ERBB2–negative disease (aHR, 1.53; 95% CI, 1.37-1.70) and triple-negative BC (aHR, 1.69; 95% CI, 1.50-1.89). Among patients with IBC, TMT receipt was associated with better BCSS compared with no TMT (aHR, 0.67; 95% CI, 0.59-0.77). From 2010 to 2020, use of TMT among patients with IBC decreased from 33.9% (111 of 327 patients) to 24.2% (52 of 215 patients), and no significant improvement in BCSS or OS over time was observed, whereas survival improved among patients with non-IBC. Conclusions and Relevance In this cohort study of stage III BC, IBC was associated with worse BCSS and OS than stage III non-IBC across all tumor subtypes. TMT use in IBC was low and decreased significantly over time. BCSS and OS did not improve over time for patients with IBC treated with TMT, whereas BCSS and OS improved for those with non-IBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.
- Harvard Medical School, Boston, Massachusetts.
- Grupo Oncológico Cooperativo del Sur, Neuquén, Argentina.
- Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy.
- Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
Zitieren
APA
Leone, J. P., Leone, J., De Placido, P., Nakhlis, F., Schlam, I., Hirko, K. A., Hazra, A., Troll, E., Bellon, J. R., Vallejo, C. T., Lin, N. U., Tolaney, S. M., & Lynce, F. (2026). Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast Cancer. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2026.5014
Vancouver
Leone JP, Leone J, De Placido P, Nakhlis F, Schlam I, Hirko KA, et al. Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast Cancer. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2026.5014
BibTeX
@article{Leone2026,
author = {Leone, José P and Leone, Julieta and De Placido, Pietro and Nakhlis, Faina and Schlam, Ilana and Hirko, Kelly A and Hazra, Aditi and Troll, Elizabeth and Bellon, Jennifer R and Vallejo, Carlos T and Lin, Nancy U and Tolaney, Sara M and Lynce, Filipa},
title = {Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast Cancer},
journal = {JAMA Network Open},
year = {2026},
doi = {10.1001/jamanetworkopen.2026.5014}
}
EUVIMED